Google
Trusted Resources: News & Events
Latest announcements and gatherings
Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation for Olinciguat for the Treatment of Sickle Cell Disease
Ironwood Pharmaceuticals, Inc., a commercial biotech company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to olinciguat (IW-1701) for the treatment of patients with sickle cell disease. Olinciguat is an orally administered soluble guanylate cyclase (sGC) stimulator.
Ironwood is currently enrolling patients in STRONG-SCD, a multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase II trial evaluating olinciguat for the potential treatment of sickle cell disease. Ironwood expects to enroll approximately 80 patients into the Phase II trial, which is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of olinciguat in patients with sickle cell disease. Further details about the trial can be found at clinicaltrials.gov using the identifier number NCT03285178.
+myBinderRelated Content
-
Acetylon Presents Preclinical Data Demonstrating the Utility of Selective HDAC1,2 Inhibition by ACY-957 to Induce Ga...Acetylon Pharmaceuticals, Inc., the lead...
-
Jazz’ Journey With Sickle Cellhttps://www.youtube.com/watch?v=OMC5wOyD...
-
Gene therapies could transform the treatment of sickle cell diseaseManny Johnson keeps catching h...
-
A multiple drug approach to preventing sickle cell crisisSickle cell disease is characterized by ...
-
CTX001 Continues to Show Promise in Severe SCDA single dose of CTX001, an experimental...
-
Nashville Doctor Performs First Successful Gene Editing Procedure on Sickle Cell Anemia Patienthttps://www.youtube.com/watch?v=s7TPRomV...
-
SCDAA News Advisory: SCDAA Statement on Exa-cel Gene TherapyOn October 31, 2023, the Food and Drug A...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.